1/31/2024 0 Comments Flowjo version 9![]() FlowJo won't recognize the attached dongle Vinko Tosevski vinko.tosevski at (2023).FlowJo won't recognize the attached dongle Efficient engineering of human and mouse primary cells using peptide-assisted genome editing. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Easy quantitative assessment of genome editing by sequence trace decomposition. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Limma powers differential expression analyses for RNA-sequencing and microarray studies. STAR: ultrafast universal RNA-seq aligner. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. Nucleic acid detection with CRISPR-Cas13a/C2c2. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Systematic discovery of recombinases for efficient integration of large DNA sequences into the human genome. Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. RNA-guided DNA insertion with CRISPR-associated transposases. Search-and-replace genome editing without double-strand breaks or donor DNA. Base editing: precision chemistry on the genome and transcriptome of living cells. Diversity and evolution of class 2 CRISPR-Cas systems. Dual function NFI factors control fetal hemoglobin silencing in adult erythroid cells. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells. The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR–Cas system. Optimization of AsCas12a for combinatorial genetic screens in human cells. Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. High-performance CRISPR–Cas12a genome editing for combinatorial genetic screening. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8 + T cells. Restoring function in exhausted CD8 T cells during chronic viral infection. Optimized retroviral transduction of mouse T cells for in vivo assessment of gene function. Molecular and cellular insights into T cell exhaustion. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Cellular uptake of the tat protein from human immunodeficiency virus. Endosomal escape pathways for delivery of biologicals. ![]() Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. A CRISPR–Cas9 delivery system for in vivo screening of genes in the immune system. In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8 + T-cell fate decisions. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells. In vivo CD8 + T cell CRISPR screening reveals control by Fli1 in infection and cancer. Delivery technologies for genome editing. Delivery technologies for T cell gene editing: applications in cancer immunotherapy. CRISPR-engineered T cells in patients with refractory cancer. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. CAR T cell immunotherapy for human cancer. CRISPR-based technologies for the manipulation of eukaryotic genomes. Development and applications of CRISPR–Cas9 for genome engineering. The promise and challenge of therapeutic genome editing.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |